ArticleFrontiers in oncology2025
Evaluating treatment strategies and machine learning based treatment recommendation system for elderly patients with high grade gliomas.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: When selecting treatment strategies, elderly high-grade glioma (eHGG) patients face challenges due to aging, comorbidities, surgical complications, and limited tolerance for intensive treatments. This study aims to evaluate the benefit of treatment strategies and develop a treatment recommendation system for eHGG patients. Methods: By propensity score matching and survival analysis, we compared the prognosis of treatment strategies, including surgery versus none, adjuvant therapies versus none, and gross total resection (GTR) versus subtotal resection (STR), among patients aged 65 and older with high-grade gliomas. A machine learning model, random survival forest, was developed to provide predictions on prognosis. The machine learning model was then used to create a personalized treatment recommendation system. An independent validation cohort was obtained from the First Affiliated Hospital of Chongqing Medical University to validate the machine learning model and the treatment recommendation system. The time-dependent AUC (tdAUC), C-index, and integrated Brier score (IBS) in the testing sets were obtained. Results: Compared to the surgery-alone group, patients who received surgery plus adjuvant therapy had significantly better overall survival. Surgery plus adjuvant therapy improved survival compared to adjuvant therapy alone. Additionally, GTR combined with adjuvant therapy showed superior overall survival compared to STR with adjuvant therapy. Subgroup analysis indicated that patients with GBM, tumor size >3 cm, localized stage, white race, Grade IV tumors, and those aged 65-72 had better survival outcomes with GTR and adjuvant therapy. The C-index, tdAUC, and 1-IBS values for the external testing cohort were 0.813, 0.876, and 0.893. We successfully developed a web-based treatment recommendation system at https://gliomas.shinyapps.io/EHGG/. This system allows users to input patient-specific features and obtain individualized treatment recommendations and detailed survival probabilities. Conclusion: Aggressive treatment, including GTR and adjuvant therapy, can enhance survival outcomes in elderly patients with high-grade gliomas. The machine learning-based personalized treatment recommendation system presents a promising reference tool for treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.